| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


* Department of Physics, University of California, Davis, California 95616; and
Center for Theoretical Biological Physics, University of California, San Diego, La Jolla, California 92093
Correspondence: Address reprint requests and inquiries to D. L. Cox, E-mail: cox{at}physics.ucdavis.edu.
A hallmark feature of prions, whether in mammals or yeast and fungi, is exponential growth associated with fission or autocatalysis of protein aggregates. We have employed a rigorous kinetic analysis to recent data from transgenic mice lacking a glycosylphosphatidylinositol membrane anchor to the normal cellular PrPC protein, which show that toxicity requires the membrane binding. We find as well that the membrane is necessary for exponential growth of prion aggregates; without it, the kinetics is simply the quadratic-in-time growth characteristic of linear elongation as observed frequently in in vitro amyloid growth experiments with other proteins. This requires both: i), a substantial intercellular concentration of anchorless PrPC, and ii), a concentration of small scrapies seeding aggregates from the inoculum, which remains relatively constant with time and exceeds the concentration of large polymeric aggregates. We also can explain via this analysis why mice heterozygous for the anchor-full/anchor-free PrPC proteins have more rapid incubation than mice heterozygous for anchor-full/null PrPC, and contrast the mammalian membrane associated fission or autocatalysis with the membrane free fission of yeast and fungal prions.
This article has been cited by other articles:
![]() |
P. Spilman, P. Lessard, M. Sattavat, C. Bush, T. Tousseyn, E. J. Huang, K. Giles, T. Golde, P. Das, A. Fauq, et al. A {gamma}-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains PNAS, July 29, 2008; 105(30): 10595 - 10600. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |